These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 14624224)

  • 1. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent.
    Mooberry SL
    Curr Opin Oncol; 2003 Nov; 15(6):425-30. PubMed ID: 14624224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of 2-methoxyestradiol: new developments.
    Mooberry SL
    Drug Resist Updat; 2003 Dec; 6(6):355-61. PubMed ID: 14744499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis.
    Plum SM; Park EJ; Strawn SJ; Moore EG; Sidor CF; Fogler WE
    BMC Musculoskelet Disord; 2009 May; 10():46. PubMed ID: 19409094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.
    Chauhan D; Catley L; Hideshima T; Li G; Leblanc R; Gupta D; Sattler M; Richardson P; Schlossman RL; Podar K; Weller E; Munshi N; Anderson KC
    Blood; 2002 Sep; 100(6):2187-94. PubMed ID: 12200384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure activity analysis of 2-methoxyestradiol analogues reveals targeting of microtubules as the major mechanism of antiproliferative and proapoptotic activity.
    Chua YS; Chua YL; Hagen T
    Mol Cancer Ther; 2010 Jan; 9(1):224-35. PubMed ID: 20053769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules.
    Kamath K; Okouneva T; Larson G; Panda D; Wilson L; Jordan MA
    Mol Cancer Ther; 2006 Sep; 5(9):2225-33. PubMed ID: 16985056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.
    Mabjeesh NJ; Escuin D; LaVallee TM; Pribluda VS; Swartz GM; Johnson MS; Willard MT; Zhong H; Simons JW; Giannakakou P
    Cancer Cell; 2003 Apr; 3(4):363-75. PubMed ID: 12726862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor.
    Brahn E; Banquerigo ML; Lee JK; Park EJ; Fogler WE; Plum SM
    J Rheumatol; 2008 Nov; 35(11):2119-28. PubMed ID: 18792999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
    Dahut WL; Lakhani NJ; Gulley JL; Arlen PM; Kohn EC; Kotz H; McNally D; Parr A; Nguyen D; Yang SX; Steinberg SM; Venitz J; Sparreboom A; Figg WD
    Cancer Biol Ther; 2006 Jan; 5(1):22-7. PubMed ID: 16357512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
    Ricker JL; Chen Z; Yang XP; Pribluda VS; Swartz GM; Van Waes C
    Clin Cancer Res; 2004 Dec; 10(24):8665-73. PubMed ID: 15623651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway.
    LaVallee TM; Zhan XH; Johnson MS; Herbstritt CJ; Swartz G; Williams MS; Hembrough WA; Green SJ; Pribluda VS
    Cancer Res; 2003 Jan; 63(2):468-75. PubMed ID: 12543804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of 2-methoxyestradiol, an Endogenous Estrogen Metabolite, in Health and Disease.
    Parada-Bustamante A; Valencia C; Reuquen P; Diaz P; Rincion-Rodriguez R; Orihuela PA
    Mini Rev Med Chem; 2015; 15(5):427-38. PubMed ID: 25723461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate.
    Pribluda VS; Gubish ER; Lavallee TM; Treston A; Swartz GM; Green SJ
    Cancer Metastasis Rev; 2000; 19(1-2):173-9. PubMed ID: 11191057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.
    Dingli D; Timm M; Russell SJ; Witzig TE; Rajkumar SV
    Clin Cancer Res; 2002 Dec; 8(12):3948-54. PubMed ID: 12473611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mitochondrial respiration by the anticancer agent 2-methoxyestradiol.
    Hagen T; D'Amico G; Quintero M; Palacios-Callender M; Hollis V; Lam F; Moncada S
    Biochem Biophys Res Commun; 2004 Sep; 322(3):923-9. PubMed ID: 15336552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression.
    Muh CR; Joshi S; Singh AR; Kesari S; Durden DL; Makale MT
    J Neurooncol; 2014 Jan; 116(1):89-97. PubMed ID: 24162827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro assessment of a computer-designed potential anticancer agent in cervical cancer cells.
    Visagie MH; Jaiswal SR; Joubert AM
    Biol Res; 2016 Nov; 49(1):43. PubMed ID: 27806731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.
    Chauhan D; Li G; Auclair D; Hideshima T; Richardson P; Podar K; Mitsiades N; Mitsiades C; Li C; Kim RS; Munshi N; Chen LB; Wong W; Anderson KC
    Blood; 2003 May; 101(9):3606-14. PubMed ID: 12480690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class I beta-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions.
    Liaw TY; Salam NK; McKay MJ; Cunningham AM; Hibbs DE; Kavallaris M
    Mol Cancer Ther; 2008 Oct; 7(10):3150-9. PubMed ID: 18852118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.